Abstract:
The present invention relates to methods for feeding of infants delivered via caesarean section and to compositions to be administered to infants delivered via caesarean section and in particular to the use of a product obtained by fermentationof milk, whey, whey protein, whey protein hydrolysate, casein, casein hydrolysate and/orlactose by lactic acid producing bacteria. Thereby it is possible to stimulate a fast colonisation of the intestinal microbiota of said infants.
Abstract:
The present invention relates to methods and nutritional compositions for stimulating the immune system, particularly in subjects with an impaired immune system such as 5 infants, said method comprising administering a composition comprising sheep milk and/or short chain oligosaccharides.
Abstract:
A food or supplement for pregnant women comprising water soluble, non-digestible saccharides is described. The composition is used to improve the flora and/or immune system o f the pregnant women, to improve the immune system of the infant and to improve the intestinal flora of the infant after birth.
Abstract:
The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section.
Abstract:
The invention relates to the use of long chain polyunsaturated fatty acids for the manufacture of a nutritional composition for feeding infants of a mother who suffered from a metabolic disorder during pregnancy and to a corresponding composition. Said composition comprises a n-3 polyunsaturated fatty acid fraction containing at least 0.1 wt docosahexaenoic acid (DHA) based on total weight of the lipid, at least 0.01 wt % n-3 docosapentaenoic acid (DPAn-3) based on total weight of the lipid, and at least 0.01 wt.% eicosapentaenoic acid (EPA) based on total weight of the lipid, wherein the sum of DHA, DPAn-3 and EPA is below 1 wt.% of total lipid.
Abstract:
The invention concerns a method for stimulating intestinal barrier integrity in a patient infected with HIV by administering to said patient composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.
Abstract:
The present invention relates to a method for enhancing the immune system and the treatment and/or prevention of immune system related disorders in a mammal, particularly newborns, said method comprising the administration of acid oligosaccharide and neutral oligosaccharide. Food compositions suitable for use in the above method are also provided.
Abstract:
Bereitgestellt werden Matrizes für die Ultraviolett Matrix-unterstützte Laserdesorptions-lonisations-Massenspektrometrie aus einem Salz eines als Protonenakzeptor reagierenden Amins und einer als Protonendonator reagierenden organischen Substanz, wobei entweder das Amin oder die organischen Substanz UV-Licht absorbiert. Diese Matrizes zeichnen sich dadurch aus, dass die Matrizes bei Raumtemperatur eine ionische Flüssigkeit darstellen, dass das Amin ausgewählt ist aus der Gruppe bestehend aus 3-Aminochinolin, Pyridin, einem primären Amin, an dessen N-Atom ein Phenylrest oder ein gerader oder verzweigter, gesättigter C 1 -C 11 -Alkylrest, der durch eine OH-Gruppe substituiert sein kann, gebunden ist, einem sekundären und tertiären Amin, an dessen N-Atom zwei oder drei Reste gebunden sind, die gleich oder verschieden sein können und bei denen es sich um einen geraden oder verzweigten, gesättigten C 1- C 8 -Alkylrest, der durch eine OH-Gruppe substituiert sein kann, und einen Phenylrest handelt, Imidazol und den C- und/oder N-alkylierten Imidazolderivaten und dass die organische Substanz ausgewählt ist aus der Gruppe bestehend aus 2,5-Dihydroxybenzoesäure sowie den Isomeren Davon,2-Hydroxy-5-methoxy-benzoesäure sowie den Isomeren davon, Picolin-säure, 3-Hydroxypicolin-säure, Nikotinsäure, 5-Chloro-2-mercapto-benzo-thiazol, 6-Aza-2-thiothymin, 2',4',6'-Trihydroxyacetophenon-Monohydrat, 2',6'-Di-hydroxyaceto-phenon, 9H-Pyridol[3,4-b]indol, Dithranol, trans-3-Indolacrylsäure, Osazone, Ferulasäure, 2,5-Dihydroxyacetophenon, 1-Nitrocarbazol, 7-Amino-4-methylcumarin, 2-(p-Hdroxyphenylazo)-benzoesäure, 8-Aminopyrene-2,3,4-trissulfonsäure, 2-[2E-3-(4-tert-butylphenyl)-2-methylprop-2-enylidene]malonitril (DCTB), 4-Methoxy-3-hydroxyzimtsäure und 3,4-Dihydroxyzimtsäure. Mit diesen flüssigen Matrizes können fehlerfreiere und reproduzierbarere Analysenwerte erhalten werden, wobei insbesondere die Verknüpfung der reinen massenspektrometrischen Analyse mit den zusätzlichen Erkenntnissen aus enzymatischen Reaktionen/Modifikationen mit der Möglichkeit eines Monitoring gegeben ist.
Abstract:
The invention relates to the use of neutral straight-chain or branched oligosaccharides for preventing the invasion and infection of mammal cells by pathogens and for fighting diseases caused by such pathogens. The invention also relates to food, dietetic products and pharmaceutical agents containing said oligosaccharides. Said oligosaccharides consist of a base unit of general formula (I), and between 0 and 19 other units of general formula (II), which are linked directly or indirectly to the base unit. In said formulae, Gal represents a galactose monosaccharide unit; Glc represents a glucose monosaccharide unit; HexNAc represents an N-acetylated galactosamine or glucosamine monosaccharide unit (GalNAc or GlcNAc); the radicals R independently represent a beta 1-3 or beta 1-6 glycosidic link to the HexNAc monosaccharide unit of the next [Gal-HexNAc] unit of general formula (II), and on a terminal [Gal-HexNAc] unit, a deoxyhexose radical which is linked to the galactose monosaccharide unit of said terminal [Gal-HexNAc] unit, or said radicals R are not present; and a terminal [Gal-HexNAc] unit, wherein the radical(s) R represent a deoxyhexose radical, can have another deoxyhexose radical on the HexNAc monosaccharide unit.